Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

278 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-10

Study Completion Date

2022-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial will evaluate the safety and immunogenicity of: i) measles vaccine (CAM-70) after primary dose at 6 months (MV1) and booster vaccination at 12 months (MV2); ii) a single dose of varicella vaccination at 18 months; and iii) a single dose of hepatitis-A vaccination at 18 months in HIV-exposed and HIV-unexposed South African children.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067)

NCT00312858

Hepatitis A Virus

COMPLETED PHASE4

DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants

NCT02817451

Diphtheria Tetanus Pertussis +3 more

COMPLETED PHASE3

Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects

NCT00317109

Infections, Meningococcal

COMPLETED PHASE3

the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines

NCT07338851

Polio Measles Rubella +2 more

NOT_YET_RECRUITING

A Study of 2 Doses of VAQTA™ in Healthy Children 12 to 23 Months of Age (V251-069)

NCT00835380

Hepatitis A Virus Infection

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Measles vaccine (MV) can reduce childhood mortality and is currently recommended to all South African children aged 6 months. Only one study has examined the safety and immunogenicity of the recommended CAM-70 measles vaccine strain in children under 9 months of age. In addition, there are limited data on the safety and immunogenicity of varicella vaccine (VV) and Hepatitis-A vaccination (Hep-AV) in HIV-exposed and HIV-unexposed children in Sub-Saharan Africa.

This is a prospective, observational cohort study nested within a larger randomized, open-label trial on pneumococcal-conjugate vaccine (PCV) titled PCV1+1. 70 HIV-exposed and 200 HIV-unexposed children will be enrolled at Chris Hani Baragwanath Academic Hospital (CHBAH) and neighbouring primary health clinics.

Immune responses to the vaccines will be measured as rate of seroconversion, rate of seroprotection, and geometric mean titres (GMT) one month post primary immunization (MV1, VV, Hep-AV) and one month post booster dose (MV2). In addition, pre-vaccination and medium long-term antibody levels at 4.5 months, 12 months and 18 months will be evaluated. Number of adverse events in all immunized infants will be recorded throughout the study duration and compared between groups. Long-term antibody levels at 3, 4 and 5 years of age will be measured during annual follow-up visits.

This study will add to the current evidence on immunizing infants with MV (CAM-70) at 6 and 12 months of age. Data will be stratified by HIV-exposure and HIV-infection, thereby offering insight in the influence of HIV on post-vaccination immune responses. The findings on VV/Hep-AV safety, immunogenicity and seroprevalence will be useful to informing future immunization policies in Sub-Saharan Africa.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Measles Varicella Hepatitis A

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Participants receive measles vaccine as part of routine medical care at 6 and 12 months of age. Half of the participants will receive varicella vaccine at 18 months of age and the other half will receive hepatitis-A at 18 months of age. All vaccines are administered according to their approved dosages, formulations and indications.

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HIV-unexposed children

HIV-unexposed children enrolled in a randomized open label study on the pneumococcal conjugate vaccine (PCV1+1) will be invited to participate in this study. Children enrolled in the PCV1+1 study will receive all vaccines included in the South African public immunization program. Measles vaccine (0.5 mL, subcutaneous injection) will be adminstered at 6 months of age and 12 months of age. Varicella vaccine (0.5 mL, subcutaneous injection) or Hepatitis-A vaccine (0.5 mL, intra-muscular injection) will be administered to the participants at 18 months of age as an additional benefit for participating in the study.

Group Type OTHER

Measles vaccine

Intervention Type BIOLOGICAL

All participants will receive measles vaccine at 6 and 12 months of age, according to the South African immunization schedule. All study vaccines are currently licensed in South Africa and will be administered according to their approved dosages, formulations and indications.

Hepatitis-A vaccine

Intervention Type BIOLOGICAL

Half of the participants (n=135) will receive hepatitis-A vaccine at 18 months of age.

Varicella vaccine

Intervention Type BIOLOGICAL

Half of the participants (n=135) will receive varicella vaccine at 18 months of age.

HIV-exposed children

A cohort of HIV-exposed children will be recruited. Measles vaccine (0.5 mL, subcutaneous injection) will be adminstered at 6 months of age and 12 months of age. Varicella vaccine (0.5 mL, subcutaneous injection) or Hepatitis-A vaccine (0.5 mL, intra-muscular injection) will be administered to the participants at 18 months of age as an additional benefit for participating in the study.

Group Type OTHER

Measles vaccine

Intervention Type BIOLOGICAL

All participants will receive measles vaccine at 6 and 12 months of age, according to the South African immunization schedule. All study vaccines are currently licensed in South Africa and will be administered according to their approved dosages, formulations and indications.

Hepatitis-A vaccine

Intervention Type BIOLOGICAL

Half of the participants (n=135) will receive hepatitis-A vaccine at 18 months of age.

Varicella vaccine

Intervention Type BIOLOGICAL

Half of the participants (n=135) will receive varicella vaccine at 18 months of age.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Measles vaccine

All participants will receive measles vaccine at 6 and 12 months of age, according to the South African immunization schedule. All study vaccines are currently licensed in South Africa and will be administered according to their approved dosages, formulations and indications.

Intervention Type BIOLOGICAL

Hepatitis-A vaccine

Half of the participants (n=135) will receive hepatitis-A vaccine at 18 months of age.

Intervention Type BIOLOGICAL

Varicella vaccine

Half of the participants (n=135) will receive varicella vaccine at 18 months of age.

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Measles vaccine (MeasBio) 0.5 mL Hepatitis-A vaccine (Varilrix) 0.5 mL Varicella vaccine (Avaxim Paediatric) 0.5 mL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Aged ≤18 weeks;
2. Parent/guardian able to provide informed consent;
3. Available for the duration of the study;
4. Enrolled as a participant in the PVC1+1 trial AND born to HIV-uninfected woman; OR Born to HIV-infected mother AND infant CD4% ≥25% if HIV-infected;
5. Birth weight \>2499g AND weight of \>3.5 kg at time of proposed enrolment;
6. Being a healthy child (except for HIV status in HIV-exposed cohort) based on medical history and physical examination by the study staff.

Exclusion Criteria

1. Significant major congenital abnormalities;
2. Received measles vaccination, varicella vaccination or hepatitis-A vaccination since birth;
3. Previous hospitalization for respiratory illness following discharge from hospital at birth;
4. Known allergy to vaccine components;
5. Febrile illness (axillary temperature ≥37.8°C) at time of screening;
6. Known or suspected immunodeficiency condition other than HIV;
7. Planning to relocate outside of the study area during the study period;
8. Receipt of blood transfusion or any other blood products (including immunoglobulins) since birth, receipt of such products during the course of the study will require withdrawal of the child from the study;
9. History of confirmed measles, varicella or hepatitis-A disease since birth.

Minimum Eligible Age

18 Weeks

Maximum Eligible Age

19 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes